Filtered By:
Source: Thrombosis Research

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 221 results found since Jan 2013.

Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)
After solid organ or hematopoietic stem cell transplantation (HSCT), the risk of arterial or venous thromboembolism (VTE) is high (1 –7). Oral anticoagulation represents the mainstay for stroke prevention in atrial fibrillation (SPAF) and VTE treatment. The pharmacodynamic and pharmacokinetic profiles of vitamin k antagonists (VKA) represent a challenge especially in the setting of transplantation, also due to the high risk of bleeding (8) and due to complex co-medications of transplant recipients.
Source: Thrombosis Research - April 23, 2020 Category: Hematology Authors: Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Luise Tittl, Katja Sockel, Jan Moritz Middecke, Martin Bornh äuser Tags: Letter to the Editors-in-Chief Source Type: research

Increased prevalence of VTE reported by Klok and colleagues, the numbers don't add up
In this study the authors report that 31% of patients met the composite outcome of having a thrombotic complication which they define as having a pulmonary embolism, deep vein thrombosis, or an ischemic stroke. The study included 184 patients with 31 patients having a thrombotic complication. This adds up to an incidence of 16.8%, not 31%.
Source: Thrombosis Research - April 25, 2020 Category: Hematology Authors: Yonatan Y. Greenstein Tags: Letter to the Editors-in-Chief Source Type: research

Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation
Efficacy and safety of vitamin K antagonists (VKAs) is optimised in atrial fibrillation (AF) patients when the International Normalised Ratio (INR) is 2.0 –3.0. Anticoagulation control comparing different ethnic groups is limited, although epidemiological studies suggest poorer INR control in non-white cohorts.
Source: Thrombosis Research - May 5, 2020 Category: Hematology Authors: Hanis Zulkifly, Paola Cheli, Ivana Lutchman, Ying Bai, Gregory Y.H. Lip, Deirdre A. Lane Tags: Full Length Article Source Type: research

In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease
Risk factors contributing to heightened thrombosis in pediatric congenital heart disease (CHD) patients are not fully understood. Among the neonatal CHD population, those presenting with single ventricular physiology are at the highest risk for perioperative thrombosis. The von Willebrand factor and ADAMTS13 interactions have emerged as causative risk factors for pediatric stroke and could contribute to heightened thrombosis in CHD neonates.
Source: Thrombosis Research - May 30, 2020 Category: Hematology Authors: Upendra K. Katneni, David D. Holcomb, Nancy E. Hernandez, Nobuko Hamasaki-Katagiri, Ryan C. Hunt, Haim Bar, Juan C. Ibla, Chava Kimchi-Sarfaty Tags: Full Length Article Source Type: research

Increased rates of hand ischemia following arterial cannulation in patients with severe COVID19-related pneumonia
Thrombotic complications in patients with COVID19 infection are increasingly reported due to the hypercoagulable state induced by the disease [1 –3]. In particular, arterial thromboembolism has been described in up to 4% of patients, with ischemic stroke being the most common thrombotic event [2]. While catheter-related upper extremity venous thromboses are anecdotally reported [4,5], at the moment no reports are available regarding upper extremity arterial thrombosis following cannulation.
Source: Thrombosis Research - June 14, 2020 Category: Hematology Authors: Walter Dorigo, Aaron Fargion, Laura Paperetti, Roberto Falso, Manuela Bonizzoli, Paolo Fontanari, Loredana Poggesi, Carlo Pratesi Tags: Letter to the Editors-in-Chief Source Type: research

Erythrocyte-rich thrombi related to serum iron contribute to single stent retrieval and favorable clinical outcomes in acute ischemic stroke by endovascular treatment
Erythrocyte-rich thrombi seem to be associated with favorable clinical outcomes of patients with AIS by endovascular treatment (EVT), as observed from previous studies. However, only few studies show whether erythrocyte-rich thrombi can be associated with favorable clinical outcomes by EVT and which factor can be related to erythrocyte-rich thrombi. This retrospective study aimed to evaluate the relationship between erythrocyte-rich thrombi and favorable clinical outcomes and further explored factors associated with erythrocyte-rich thrombi.
Source: Thrombosis Research - June 23, 2020 Category: Hematology Authors: Mingli Liu, Zhongfei Hao, Ruiyan Li, Jinquan Cai, Yongli Li, Chuanlu Jiang Tags: Full Length Article Source Type: research

Incidence and prevalence of venous thromboembolism in Norway 2010 –2017
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a major cause of mortality and morbidity, and is associated with reduced survival, substantial healthcare costs, and high recurrence rates [1]. It is the third-leading cardiovascular disorder, after myocardial infarction and stroke with approximately 10 million global cases diagnosed annually [2].
Source: Thrombosis Research - July 6, 2020 Category: Hematology Authors: Waleed Ghanima, Ellen Brodin, Anna Schultze, Leah Shepherd, Dimitra Lambrelli, Maria Ulvestad, Sreeram Ramagopalan, Sigrun Halvorsen Tags: Letter to the Editors-in-Chief Source Type: research

Thromboembolic events related to atrial fibrillation during the COVID-19 epidemic in Denmark
The COVID-19 epidemic has threatened to overwhelm the health-care systems of European countries resulting in government decisions of extensive societal lockdowns. There have been considerable concerns regarding the collateral effects of the COVID-19 epidemic overshadowing the care of patients with other medical conditions including cardiovascular diseases. Of interest, decreases in the registered incidences of atrial fibrillation (AF) and ischemic stroke have been reported [1,2]. AF is a common reason for physician contact and AF patients are often recommended treatment with oral anticoagulants to mitigate the associated r...
Source: Thrombosis Research - July 29, 2020 Category: Hematology Authors: Peter Vibe Rasmussen, Paul Blanche, Jarl Emanuel Strange, Jawad Haider Butt, Frederik Dalgaard, Kristian Kragholm, Matthew Phelps, Gunnar Gislason, Morten Lock Hansen Tags: Letter to the Editors-in-Chief Source Type: research

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19
Covid-19 has significant implications of hematologic systems, including lymphocytopenia, thrombocytopenia, ischemic or hemorrhagic stroke, pulmonary thromboembolism, and myocardial infarction [1,2]. Iwasaki et al. reported that the pathogen of Covid-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can induce immune dysfunction, inflammation, and antibody-dependent enhancement by activating host cells via the Fc γIIa receptor in the same way as SARS-CoV-1 [3].
Source: Thrombosis Research - August 2, 2020 Category: Hematology Authors: Ching-Tai Huang, Shao-Yun Hsu, Ko-Wei Chang, Chung-Guei Huang, Cheng-Ta Yang, Ming-Huei Cheng Tags: Letter to the Editors-in-Chief Source Type: research

A diagnosis of atrial fibrillation is not a predictor for pulmonary embolism
Atrial fibrillation causes stroke by embolization of blood clots from the left atrium. This suggests that it also can cause pulmonary embolism through embolization of thrombi from the right atrium. Our objective was to investigate if atrial fibrillation is an independent risk factor for pulmonary embolism.
Source: Thrombosis Research - August 9, 2020 Category: Hematology Authors: Leif Friberg, Emma Svennberg Tags: Full Length Article Source Type: research

COVID-19 versus HIT hypercoagulability
A striking feature of COVID-19 is the high frequency of thrombosis, particularly in patients who require admission to intensive care unit because of respiratory complications (pneumonia/adult respiratory distress syndrome). The spectrum of thrombotic events is wide, including in situ pulmonary thrombosis, deep-vein thrombosis and associated pulmonary embolism, as well as arterial thrombotic events (stroke, myocardial infarction, limb artery thrombosis). Unusual thrombotic events have also been reported, e.g., cerebral venous sinus thrombosis, mesenteric artery and vein thrombosis.
Source: Thrombosis Research - August 8, 2020 Category: Hematology Authors: Theodore E. Warkentin, Scott Kaatz Tags: Review Article Source Type: research

Determinants of left atrial thrombus or spontaneous echo contrast in nonvalvular atrial fibrillation
The CHADS2 and CHA2DS2-VASc scores are well-established clinical scales to estimate the risk of stroke in patients with atrial fibrillation (AF). However, the predictive power of the two scales concerning left atrial thrombus (LAT) or spontaneous echo contrast (SEC) has not been well investigated. Therefore, we investigated the predict power of CHADS2 and CHA2DS2-VASc scores concerning LAT/SEC; identified clinical, echocardiographic and laboratory predictors of LAT/SEC in addition to the CHADS2 and CHA2DS2-VASc scores; and derived a new scale to predict LAT/SEC accurately, it might improve thromboembolic risk stratificatio...
Source: Thrombosis Research - August 6, 2020 Category: Hematology Authors: Deheng Han, Yanan Chu, Yakui Wu, Xingxiang Wang Tags: Full Length Article Source Type: research

Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis
To recommend the proper anticoagulant drug and its dose for patients with atrial fibrillation (AF) and heart failure (HF), we conducted a network meta-analysis (NMA) to make the comparisons among non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin with regard to efficacy (stroke or systemic embolism) and safety (major bleeding).
Source: Thrombosis Research - August 12, 2020 Category: Hematology Authors: Hao Jin, Kongbo Zhu, Lina Wang, Wangjuan Zhou, Hong Zhi Tags: Review Article Source Type: research

Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant
Atrial fibrillation (AF) is associated with increased risk of stroke and thromboembolism. Patients with AF have a higher incidence of renal impairment, which may influence the risks of systemic thromboembolism or bleeding. We determined how different oral anticoagulants affect plasma clot properties and whether progressive renal dysfunction affects plasma clot properties in patients on warfarin.
Source: Thrombosis Research - November 7, 2020 Category: Hematology Authors: Ahsan A. Khan, Lewis J. Hardy, Eduard Shantsila, Yee C. Lau, Helen Philippou, Gregory Y.H. Lip Source Type: research

The effect of race on composite thrombotic events in patients with COVID-19
COVID-19 associated coagulopathy and mortality related to thrombotic complications have been suggested as biological mediators in racial disparities related to COVID-19. We studied the adjusted prevalence of acute ischemic stroke, pulmonary embolism, myocardial infarction, and deep venous thrombosis stratified by race in hospitalized patients in one New York City borough during the local COVID-19 surge. The multi-racial cohort included 4,299 patients hospitalized with COVID-19, 9% of whom were white, 40% black, 41% Hispanic and 10% Asian or other.
Source: Thrombosis Research - December 21, 2020 Category: Hematology Authors: Charles Esenwa, Santiago R. Unda, David J. Altschul, Nikunj K. Patel, Avinash Malaviya, Johanna Seiden, Andrea Lendaris, Khadean Moncrieffe, Daniel L. Labovitz Tags: Letter to the Editors-in-Chief Source Type: research